Answers are grounded in this paper and cite their sources.
Objectives The HYACINCT trial will investigate the role of dose-adapted hypofractionated pelvic radiotherapy in patients with locally advanced cervical cancer who are ineligible for cisplatin. This dummy run evaluated the feasibility of the protocol treatment planning objectives using intensity-modulated radiotherapy (IMRT) and volumetric arc therapy (VMAT). Material and Methods The HYACINCT protocol defines a set of guidelines for image acquisition, target and organ delineation, and treatment planning objectives. Fifteen dummy cases were prepared, five each for three levels of dose requirements: 40 Gy without boost, and with boost to 45 Gy and to 48 Gy. IMRT and VMAT plans were prepared for each case, evaluated and assigned penalty and compliance scores according to planning objectives, and subjected to quality control. IMRT and VMAT plans were compared in terms of treatment plan quality (target coverage, penalty, and compliance scores), and treatment delivery. Tumor extent (T-stage, T-score), nodal status, and PTV volumes (in cc) were examined as potential determinants of penalty and compliance scores. Results IMRT was able to meet the planning objectives for all but one case; and VMAT, for all cases. All plans passed the quality control check. IMRT and VMAT were equivalent in terms of target coverage and penalty and compliance scores, but the latter was associated with better treatment delivery. T-score was a determinant for the penalty score. Conclusion The HYACINCT radiotherapy protocol is feasible with either IMRT or VMAT. VMAT may be beneficial in more extensive cases, as measured by the T-score.
No takes yet. Share an insight, caveat, or question.
Bacorro et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: